| Packard Center for ALS Research at Johns Hopkins |
New ALS Drug Slips Through Telling Phase II Clinical TrialsScienceDaily (Jan. 14, 2010) — A drug already used to treat symptoms of epilepsy has potential to slow the muscle weakening that comes with amyotrophic lateral sclerosis (ALS), scientists report after completing a Phase II clinical trial -- an early, small-scale test to show if the drug works and continues to be safe. A report online December 4 in the journal Amyotrophic Lateral Sclerosis says the drug talampanel showed some ability to slow the loss of major daily life activities such as speaking, walking and dressing that typically slip away as the disease progresses. The drug is a member of the benzodiazepine family -- anti-anxiety and muscle-relaxing agents that work in the brain and spinal cord. | Events
| |
 | © 2011, The Robert Packard Center for ALS Research at Johns Hopkins. All rights reserved. |
